US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

ADPT Adaptive Biotechnologies Corporation

5.96

-0.53 (-8.17%)

12 Nov 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/22/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/23/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Stacy Lee Taylor

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Adaptive Biotechnologies (NASDAQ:ADPT)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Adaptive Biotechnologies.

Adaptive Biotechnologies (NASDAQ:ADPT)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas Adaptive Biotechnologies.

Noticias sobre Adaptive Biotechnologies Corporation ADPT

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Viernes 8 de Noviembre 2024 (4 días hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 7 de Noviembre 2024 (5 días hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 7 de Noviembre 2024 (5 días hace) • Edgar (US Regulatory)

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
Jueves 7 de Noviembre 2024 (5 días hace) • GlobeNewswire Inc.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Jueves 7 de Noviembre 2024 (6 días hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 10 de Octubre 2024 (1 mes hace) • Edgar (US Regulatory)

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
Miércoles 9 de Octubre 2024 (1 mes hace) • GlobeNewswire Inc.

Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Jueves 29 de Agosto 2024 (2 meses hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 23 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Jueves 22 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Jueves 22 de Agosto 2024 (3 meses hace) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 1 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Adaptive Biotechnologies Corporation Artículos de Noticias

Gold vs US Dollar

Bank of America

JP Morgan Chase

American Express

Health Care Select Sector

US Dollar vs MXN

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones